July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Optical Coherence Tomography Angiography Findings in Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor
Author Affiliations & Notes
  • Eung-Suk Kim
    Ophthalmology, Kyung Univ Medical Center, Seoul, Korea (the Democratic People's Republic of)
  • Jae Min Kim
    Ophthalmology, Kyung Univ Medical Center, Seoul, Korea (the Democratic People's Republic of)
  • Sung Rae Noh
    Ophthalmology, Kyung Univ Medical Center, Seoul, Korea (the Democratic People's Republic of)
  • Kiyoung Kim
    Ophthalmology, Kyung Univ Medical Center, Seoul, Korea (the Democratic People's Republic of)
  • Kunho Bae
    Ophthalmology, Kyung Univ Medical Center, Seoul, Korea (the Democratic People's Republic of)
  • Seung-Young Yu
    Ophthalmology, Kyung Univ Medical Center, Seoul, Korea (the Democratic People's Republic of)
  • Footnotes
    Commercial Relationships   Eung-Suk Kim, None; Jae Min Kim, None; Sung Rae Noh, None; Kiyoung Kim, None; Kunho Bae, None; Seung-Young Yu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5448. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eung-Suk Kim, Jae Min Kim, Sung Rae Noh, Kiyoung Kim, Kunho Bae, Seung-Young Yu; Optical Coherence Tomography Angiography Findings in Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5448.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze microvascular changes of retinal vein occlusion patients using optical coherence tomography angiography(OCTA) before and after anti-vascular endothelial growth factor(VEGF) therapy

Methods : Retrospective review of medical record of patients with secondary macular edema to retinal vein occlusion treated with anti-VEGF and a minimum follow-up of 3 months. Best-corrected visual acuity(BCVA), central retinal thickness(CRT) were assessed before and after treatment. The area of capillary non-perfusion, foveal avascular area, vessel density and perfusion index was evaluated with OCTA

Results : The study analyzed 40 eyes of 40 patients (mean ages, 65.4 years), including 11 cases of central RVO, 23 cases of branch RVO and 6 cases of hemi-central RVO. All patients received anti-VEGF treatment of RVO with secondary macular edema at least once more intravitreal injection. The mean follow-up period was 5.5 months. At final visit, the logMAR BCVA significantly improved from 0.51±0.13 to 0.28±0.17 (p<0.001) and mean central retinal thickness significantly decreased from 405.13±142.02μm to 294.50±102.73μm (p<0.001). The disruption of perifoveal capillary, the number of intraretinal cyst and venous dilatation in retinal superficial and deep capillary layers on OCTA was significantly decreased after treatment using OCTA. The area of capillary non-perfusion after treatment was decreased rather than baseline

Conclusions : The study showed improvement of impaired retinal vascular flow and areas of capillary non-perfusion after anti-VEGF treatment on OCTA. OCTA may offer effective and non-invasive diagnostic tool for RVO with especially observing microvascular changes including capillary perfusion status

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×